ScripAlready riding high with positive early data for its long-acting GLP-1 analog candidate MET-0971, Metsera grabbed attention again on June 9 with Phase I data for its amylin analog MET-233i, which prod
ScripBayer’s hopes of catching up with Boehringer Ingelheim’s small molecule HER2 inhibitor zongertinib have been boosted by regulators in the US putting sevabertinib, its same-class candidate for lung can
ScripWhile significant progress has been made in the treatment of non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC) has seen fewer advances and patients continue to have limited treatment o
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Quiver, QurAlis To Combine Tech Platfor